ALK-Positive Large B-Cell Lymphoma Specialist Access & Advanced Care

ALK-positive large B-cell lymphoma (ALK+ LBCL) is a rare, aggressive B-cell lymphoma defined by rearrangement of the ALK gene, most commonly producing the CLTC-ALK fusion. It differs from conventional diffuse large B-cell lymphoma (DLBCL) in several key ways: it predominantly affects younger adults, it often expresses plasma cell-like markers (CD138, EMA) while losing conventional B-cell markers (CD20 may be absent), and it carries the ALK driver that is targetable by ALK inhibitors. It is also distinct from ALK-positive anaplastic large cell lymphoma (ALCL), which arises from T cells rather than B cells.

ALK+ LBCL is frequently misclassified because its unusual immunophenotype — ALK-positive but CD20-negative or dim, with plasma cell markers — overlaps with other entities including ALK-positive ALCL and plasmablastic lymphoma. Misdiagnosis directly affects treatment: ALCL is treated with brentuximab vedotin-containing regimens and plasmablastic lymphoma has its own protocols. The correct diagnosis of ALK+ LBCL requires an expert haematopathologist using a comprehensive panel of immunohistochemistry markers and often FISH for ALK rearrangement. A second pathology opinion from a specialist lymphoma centre is advisable in all cases.

Yes — the ALK rearrangement provides a rational biological target for ALK kinase inhibitors, and case reports and small series have described responses to crizotinib and next-generation ALK inhibitors (lorlatinib, alectinib, brigatinib) in ALK+ LBCL. However, ALK inhibitors are not formally approved for this indication, as formal clinical trials in this rare entity are lacking. Use is off-label at specialist centres, typically in the relapsed/refractory setting or in combination with chemotherapy in frontline treatment at experienced programmes. Compassionate use applications and clinical trial enrolment are the recommended pathways.

Rituximab targets the CD20 antigen on B cells. In ALK+ LBCL, the tumour cells undergo a plasma cell-like differentiation programme driven by ALK signalling, which frequently results in loss or marked reduction of CD20 expression. When CD20 is absent or very dim, rituximab has no meaningful target on the tumour cells and is unlikely to be beneficial. This is why CHOP without rituximab, or regimens used for CD20-negative lymphomas (such as dose-adjusted EPOCH), may be more appropriate than standard R-CHOP. CD20 expression should always be formally assessed before treatment decisions are made.

Durable remission is achievable in a subset of patients — particularly young adults with limited-stage disease who receive intensive treatment. Published case series describe long-term remissions, especially in patients with localised disease and low IPI scores. However, as a rare and biologically aggressive lymphoma, the disease does carry meaningful relapse risk, and the evidence base is too limited to make confident generalised statements about outcomes. Each patient's situation depends on their specific stage, molecular features, treatment received, and response. An individualised prognosis discussion with a specialist lymphoma team is important.

CD19-directed CAR-T products (such as axicabtagene ciloleucel and lisocabtagene maraleucel) are approved for relapsed/refractory large B-cell lymphomas and may be applicable in ALK+ LBCL provided that CD19 expression is confirmed. Even when CD20 is lost or diminished, CD19 expression may be retained, making CAR-T a viable option in this subset. Eligibility requires formal CD19 expression assessment by IHC or flow cytometry, as well as meeting the standard fitness criteria for CAR-T (no active CNS disease, adequate organ function, prior lymphodepleting chemotherapy).

The most important first steps are: confirming the diagnosis with an expert haematopathologist (a second pathology opinion is strongly advised), obtaining complete staging with PET-CT and bone marrow biopsy, and being referred to a specialist lymphoma centre with experience in rare aggressive B-cell lymphomas. Fertility preservation should be arranged urgently in patients of reproductive age before starting any treatment. Patients and families should ask their treating team whether any clinical trials are open and whether ALK inhibitor access is available.

ALK-negative large B-cell lymphomas (the majority of DLBCL) lack ALK gene rearrangement and typically express CD20, making them amenable to rituximab-based therapy and CD20-targeted approaches. ALK+ LBCL is defined by ALK rearrangement, frequently lacks CD20, and carries a plasma cell-like immunophenotype — features that distinguish it diagnostically and therapeutically. The presence of ALK also makes the tumour targetable with ALK kinase inhibitors, an option not available in ALK-negative disease. Outcomes may differ, though comparisons are difficult given the extreme rarity of ALK+ LBCL.

Yes. CancerFax supports patients and families facing an ALK+ LBCL diagnosis by reviewing pathology reports and staging workups, coordinating second opinions from expert haematopathologists and lymphoma specialists, identifying ALK inhibitor access pathways and clinical trial enrolment opportunities, and facilitating coordination with specialist lymphoma programmes at leading centres in India, China, and internationally. Please share your medical reports through the CancerFax portal or contact our team to begin the process.